Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to assess whether administration of Arginine Butyrate + ganciclovir/valganciclovir for up to three 21-day cycles is tolerable, and results in partial or complete responses in patients with EBV(+) lymphoid malignancies.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00917826
Study type Interventional
Source HemaQuest Pharmaceuticals Inc.
Contact
Status Terminated
Phase Phase 2
Start date September 2008

See also
  Status Clinical Trial Phase
Completed NCT00354120 - Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant Phase 2/Phase 3